Robert Alexander - Allakos CEO, Director
| ALLK Stock | USD 0.29 0.02 6.45% |
CEO
Dr. Robert D. Alexander Ph.D., is President, Chief Executive Officer, Director of the Company. He has served as a member of our board of directors since May 2017, as our Chief Executive Officer since April 2017 and as our President since November 29, 2017. He previously served as a member of our board of directors from December 2012 until June 2013. From December 2013 to April 2017, Dr. Alexander served as Chief Executive Officer of ZS Pharma, where he also served as a member of the board of directors, including as Chairman from March 2013 to March 2014. From November 2005 to March 2013, Dr. Alexander served as a Director at Alta Partners, a VC firm in life sciences. In addition, he acted as Executive Chairman and interim Chief Executive Officer of SARcode Biosciences, a biopharmaceutical company. During his time at Alta, he led investments in SARcode Biosciences, Lumena Pharmaceuticals, ZS Pharma and Allakos. Previously, Dr. Alexander was a Principal in MPM Capitals BioEquities fund where he sourced opportunities and led due diligence efforts for both public and private investments. Dr. Alexander also previously worked in the Business Development group at Genentech, a biotechnology company, where he was responsible for sourcing and screening product opportunities based on scientific merit and strategic fit, leading diligence teams and negotiating terms and definitive agreements. He is currently a director at Allena Pharmaceuticals since 2017.
| Age | 55 |
| Tenure | 8 years |
| Professional Marks | Ph.D |
| Address | 825 Industrial Road, San Carlos, CA, United States, 94070 |
| Phone | 650 597 5002 |
| Web | https://www.allakos.com |
Robert Alexander Latest Insider Activity
Tracking and analyzing the buying and selling activities of Robert Alexander against Allakos stock is an integral part of due diligence when investing in Allakos. Robert Alexander insider activity provides valuable insight into whether Allakos is net buyers or sellers over its current business cycle. Note, Allakos insiders must abide by specific rules, including filing SEC forms every time they buy or sell Allakos'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Robert Alexander over two months ago Disposition of 32466 shares by Robert Alexander of Allakos at 1.1 subject to Rule 16b-3 | ||
Robert Alexander over three months ago Disposition of 37311 shares by Robert Alexander of Allakos at 0.58 subject to Rule 16b-3 | ||
Robert Alexander over six months ago Disposition of 1497 shares by Robert Alexander of Capital One at 136.36 subject to Rule 16b-3 | ||
Robert Alexander over six months ago Disposition of 9143 shares by Robert Alexander of Allakos at 6.4 subject to Rule 16b-3 |
Allakos Management Efficiency
The company has return on total asset (ROA) of (0.4875) % which means that it has lost $0.4875 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2168) %, meaning that it created substantial loss on money invested by shareholders. Allakos' management efficiency ratios could be used to measure how well Allakos manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.92. The value of Return On Capital Employed is expected to slide to -1.14. At this time, Allakos' Total Current Liabilities is quite stable compared to the past year. Liabilities And Stockholders Equity is expected to rise to about 370.4 M this year, although the value of Change To Liabilities is projected to rise to (8.3 M).Similar Executives
| Found 12 records | CEO Age | ||
| Jeremy MBA | Day One Biopharmaceuticals | 54 | |
| Jason Okazaki | Assembly Biosciences | 49 | |
| Kathryn MBA | Blueprint Medicines Corp | 49 | |
| Steven MD | Sana Biotechnology | 55 | |
| JD Esq | Annexon | 57 | |
| Jason JD | Assembly Biosciences | 49 | |
| Scott Struthers | Crinetics Pharmaceuticals | 62 | |
| Mark Goldsmith | Revolution Medicines | 63 | |
| Pascal DVM | Atara Biotherapeutics | 61 | |
| John Houston | Arvinas | 64 | |
| Craig Collard | Heron Therapeuti | 59 | |
| Scott Wolchko | Fate Therapeutics | 55 | |
Management Performance
| Return On Equity | -1.22 | ||||
| Return On Asset | -0.49 |
Allakos Leadership Team
Elected by the shareholders, the Allakos' board of directors comprises two types of representatives: Allakos inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Allakos. The board's role is to monitor Allakos' management team and ensure that shareholders' interests are well served. Allakos' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Allakos' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Alan Chang, Director Analytics | ||
| Brad Youngblood, Head Research | ||
| Craig MD, Chief Officer | ||
| Henrik Rasmussen, Chief Medical Officer | ||
| Adam Tomasi, President | ||
| Baird III, Chief Officer | ||
| Mary Cromwell, Chief Officer | ||
| Robert Alexander, CEO, Director | ||
| MPH MD, Chief Officer |
Allakos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Allakos a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.22 | ||||
| Return On Asset | -0.49 | ||||
| Current Valuation | (27.62 M) | ||||
| Shares Outstanding | 89.34 M | ||||
| Shares Owned By Insiders | 2.13 % | ||||
| Shares Owned By Institutions | 92.56 % | ||||
| Number Of Shares Shorted | 2.44 M | ||||
| Price To Earning | (21.26) X | ||||
| Price To Book | 0.35 X | ||||
| EBITDA | (189.91 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allakos. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Allakos Stock please use our How to buy in Allakos Stock guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allakos. If investors know Allakos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allakos listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Allakos is measured differently than its book value, which is the value of Allakos that is recorded on the company's balance sheet. Investors also form their own opinion of Allakos' value that differs from its market value or its book value, called intrinsic value, which is Allakos' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allakos' market value can be influenced by many factors that don't directly affect Allakos' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allakos' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allakos is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allakos' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.